[EN] PLASMINOGEN ACTIVATOR INHIBITOR ANTAGONISTS RELATED APPLICATIONS<br/>[FR] ANTAGONISTES DE L'INHIBITEUR DES ACTIVATEURS DU PLASMINOGÈNE
申请人:CORVAS INT INC
公开号:WO2001036351A2
公开(公告)日:2001-05-25
Compounds and pharmaceutical compositions useful as plasminogen activator inhibitor (PAI) antagonists are provided. In particular, methods of antagonizing PAI with substituted and unsubstituted aryl and heteroaryl ethers and thioethers, benzils, benzyl ethers, benzoate esters, sulfones and benzophenones are provided.
[EN] INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR FOR DECREASING BODY MASS<br/>[FR] INHIBITEURS DES ACTIVATEURS DU PLASMINOGENE DESTINES A REDUIRE LA MASSE CORPORELLE
申请人:GENSET SA
公开号:WO2003009871A2
公开(公告)日:2003-02-06
The present invention relates to the field of treating obesity related disorders. Obesity is a public health problem that is serious and widespread. Compounds, PAI Inhibitors, have been identified that reduces weight gain in animals. These compounds should be effective for reducing body mass and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.
Plasminogen activator inhibitor antagonists
申请人:Corvas International INC
公开号:US06677473B1
公开(公告)日:2004-01-13
Compounds and pharmaceutical compositions useful as plasminogen activator inhibitor (PAI) antagonists are provided. In particular, methods of antagonizing PAI with substituted and unsubstituted aryl and heteroaryl ethers and thioethers, benzils, benzyl ethers, benzoate esters, sulfones and benzophenones are provided.